Fortress Biotech Inc
NASDAQ:FBIO
Fortress Biotech Inc
Intangible Assets
Fortress Biotech Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
Intangible Assets
$28.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
36%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Intangible Assets
$52.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Intangible Assets
$17B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Intangible Assets
$22.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Intangible Assets
$424.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Intangible Assets
$1.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fortress Biotech Inc
Glance View
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 173 full-time employees. The company went IPO on 2011-11-17. Fortress has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, and at its partner companies. Its product candidates span six market areas, including oncology, rare diseases and gene therapy. The firm's commercialized products include Ximino, Targadox, Exelderm, Ceracade, Luxamend and Accutane. Its late-stage product candidates include Intravenous (IV) Tramadol, CUTX-101, MB-107 and MB-207, Cosibelimab, CK-101, CAEL-101, Triplex and CEVA101. Its product candidates also consist of MB-102 (CD123 CAR T for BPDCN), MB-101 (IL13Ra2 CAR T for Glioblastoma), MB-104, MB-106, MB-103, AVTS-001, CK-103 and ConVax. The firm operates in two operating and reportable segments: Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
See Also
What is Fortress Biotech Inc's Intangible Assets?
Intangible Assets
28.7m
USD
Based on the financial report for Sep 30, 2025, Fortress Biotech Inc's Intangible Assets amounts to 28.7m USD.
What is Fortress Biotech Inc's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
36%
Over the last year, the Intangible Assets growth was 61%.
